Voyager Therapeutics (VYGR) Equity Average (2016 - 2025)
Historic Equity Average for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $231.9 million.
- Voyager Therapeutics' Equity Average fell 3033.65% to $231.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.9 million, marking a year-over-year decrease of 3033.65%. This contributed to the annual value of $268.0 million for FY2024, which is 8151.28% up from last year.
- According to the latest figures from Q3 2025, Voyager Therapeutics' Equity Average is $231.9 million, which was down 3033.65% from $258.3 million recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' Equity Average registered a high of $338.2 million during Q2 2024, and its lowest value of $68.0 million during Q2 2022.
- Its 5-year average for Equity Average is $186.5 million, with a median of $187.6 million in 2023.
- As far as peak fluctuations go, Voyager Therapeutics' Equity Average plummeted by 4488.9% in 2022, and later skyrocketed by 20591.1% in 2023.
- Over the past 5 years, Voyager Therapeutics' Equity Average (Quarter) stood at $91.2 million in 2021, then decreased by 23.91% to $69.4 million in 2022, then skyrocketed by 197.13% to $206.3 million in 2023, then surged by 52.73% to $315.0 million in 2024, then decreased by 26.39% to $231.9 million in 2025.
- Its Equity Average stands at $231.9 million for Q3 2025, versus $258.3 million for Q2 2025 and $286.2 million for Q1 2025.